Physician profile
Min Yan
NPI 1447499710
$50,473.88
in general payments reported to CMS, 2019-2025
80 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $6,019 · 2020: $3,246 · 2021: $3,927 · 2022: $3,825 · 2023: $15K · 2024: $5,883 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Food and Beverage: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,440 · Travel and Lodging: $601 · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,585.00 |
| Food and Beverage | $11,614.53 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,440.00 |
| Travel and Lodging | $600.82 |
| Education | $215.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $16,433.69 | 2019-2025 | Tagrisso, Calquence, Lynparza |
| Agios Pharmaceuticals, INC. | $7,551.24 | 2019-2025 | Pyrukynd |
| Eisai INC. | $4,269.34 | 2021-2025 | |
| Pfizer INC. | $4,203.18 | 2019-2025 | |
| Glaxosmithkline, LLC. | $2,135.94 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Adc Therapeutics America, INC. | $2,114.55 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $1,178.11 | 2019-2025 | Opdivo, Reblozyl |
| Janssen Biotech, INC. | $1,132.59 | 2019-2025 | Rybrevant, Carvykti, Erleada |
| Merck Sharp & Dohme LLC | $1,071.73 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Takeda Pharmaceuticals U.S.A., INC. | $685.78 | 2019-2025 | Iclusig, Fruzaqla, Ninlaro |
| Novartis Pharmaceuticals Corporation | $679.53 | 2019-2025 | |
| Astellas Pharma US INC | $622.68 | 2019-2025 | Padcev, Xtandi, Xospata |
| Seagen INC. | $582.62 | 2019-2023 | Adcetris, Tukysa, Padcev |
| Celgene Corporation | $526.87 | 2019-2025 | Reblozyl, Breyanzi, Pomalyst |
| Lilly USA, LLC | $493.61 | 2019-2025 | Jaypirca, Verzenio |
Show all 80 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $324.77 | 2019-2025 | |
| Genentech USA, INC. | $324.73 | 2019-2025 | Venclexta, Tecentriq, Lunsumio |
| Array Biopharma INC | $298.11 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Bayer Healthcare Pharmaceuticals INC. | $262.55 | 2019-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $260.15 | 2019-2023 | Imbruvica, Epkinly |
| Amgen INC. | $255.40 | 2019-2023 | Blincyto, Kyprolis, Xgeva |
| Kite Pharma, INC. | $250.14 | 2020-2025 | Yescarta |
| Daiichi Sankyo INC. | $239.72 | 2019-2025 | Enhertu, Datroway |
| Exelixis INC. | $220.00 | 2019-2025 | Cabometyx |
| Abbvie INC. | $218.14 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $186.06 | 2023 | Prolaris |
| Gilead Sciences, INC. | $158.11 | 2019-2025 | Trodelvy |
| Incyte Corporation | $151.31 | 2024-2025 | Monjuvi, Jakafi |
| Acrotech Biopharma INC. | $151.19 | 2021-2025 | Beleodaq |
| Kyowa Kirin, INC. | $137.39 | 2019-2025 | Poteligeo |
| Sobi, INC | $132.94 | 2023-2025 | |
| Octapharma USA, INC. | $132.62 | 2023-2024 | Octagam Immune Globulin (Human), Panzyga |
| Vertos Medical, INC. | $131.57 | 2022 | |
| Rigel Pharmaceuticals, INC. | $127.76 | 2019-2025 | Rezlidhia, Gavreto, Tavalisse |
| Tersera Therapeutics LLC | $127.09 | 2019-2025 | Zoladex |
| Ipsen Biopharmaceuticals, INC | $124.01 | 2024-2025 | Onivyde, Somatuline Depot |
| US Oncology Corporate, INC. | $122.32 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.21 | 2019-2024 | Gilotrif |
| Regeneron Healthcare Solutions, INC. | $117.62 | 2021-2025 | Libtayo |
| Integra Lifesciences Corporation | $112.81 | 2025 | Integra, Surgimend, Omnigraft |
| Coherus Oncology, INC. | $111.77 | 2024-2025 | Loqtorzi |
| Karyopharm Therapeutics INC. | $109.18 | 2022-2025 | Xpovio |
| Taiho Oncology, INC. | $104.34 | 2019-2023 | |
| Pharmacosmos Therapeutics INC. | $103.48 | 2023-2025 | Monoferric |
| Dendreon Pharmaceuticals LLC | $95.51 | 2019 | |
| Emd Serono, INC. | $94.76 | 2019-2025 | |
| Genmab U.S., INC. | $91.03 | 2024 | Epkinly |
| Alexion Pharmaceuticals, INC. | $90.34 | 2020-2024 | Ultomiris |
| Tesaro, INC. | $81.78 | 2019 | |
| Deciphera Pharmaceuticals INC. | $78.51 | 2023-2024 | Qinlock |
| Jazz Pharmaceuticals INC. | $74.15 | 2023-2024 | |
| Springworks Therapeutics, INC. | $69.65 | 2024-2025 | Ogsiveo |
| Kci USA, INC. | $61.87 | 2020 | |
| Geron Corporation | $58.64 | 2024-2025 | Rytelo |
| Intuitive Surgical, INC. | $58.45 | 2020-2024 | |
| Clovis Oncology, INC. | $57.48 | 2019 | |
| Janssen Pharmaceuticals, INC | $55.55 | 2021-2024 | |
| Puma Biotechnology, INC. | $53.04 | 2024-2025 | |
| Iovance Biotherapeutics, INC. | $49.05 | 2025 | Amtagvi |
| Morphosys, US INC. | $48.25 | 2023 | Monjuvi |
| Beone Medicines USA, INC. | $47.54 | 2025 | Brukinsa |
| Pharmaessentia USA Corporation | $46.04 | 2024-2025 | Besremi |
| Mirati Therapeutics, INC. | $45.39 | 2023 | Krazati |
| Apellis Pharmaceuticals, INC. | $43.27 | 2023-2024 | Empaveli |
| Recordati_rare_diseases_inc. | $39.35 | 2024-2025 | Sylvant |
| Servier Pharmaceuticals LLC | $38.91 | 2023-2025 | |
| Stemline Therapeutics INC. | $35.83 | 2024 | Orserdu |
| Myovant Sciences INC. | $28.85 | 2022 | |
| Heron Therapeutics, INC. | $27.12 | 2019 | |
| Immunogen, INC. | $25.20 | 2024 | Elahere |
| Legend Biotech USA INC. | $24.21 | 2025 | Carvykti |
| Beigene USA, INC. | $23.90 | 2025 | Brukinsa |
| Sanofi-Aventis U.S. LLC | $21.72 | 2019 | |
| Sanofi US Services INC. | $20.29 | 2025 | |
| Cardinal Health 414 LLC | $20.14 | 2024 | Kit For The Preparation of Lymphoseek (Technetium Tc 99m Tilmanocept) |
| Tempus Ai, INC | $18.08 | 2025 | Xt Cdx |
| Lexicon Pharmaceuticals, INC. | $17.45 | 2019 | |
| Foundation Medicine, INC. | $13.84 | 2023 | |
| Davol INC. | $11.91 | 2020 | |
| Advanced Accelerator Applications | $8.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,930.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Min Yan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.